Evaluation and treatment of patients with progessive immunosuppression

US5296353A · kind A · utility

Assignees

• The United States of America, as represented by the Department of Health and Human Services · US
• Regents of the University of Minnesota · US

Inventors

• Augusto C. Ochoa · Windom, US
• Hiromoto Mizoguchi · Frederick, US
• John J. O'Shea · Silver Spring, US
• Dan L. Longo · Kensington, US
• Cynthia Loeffler · Bladensburg, US

Key dates

• Filing date: Apr 6, 1992
• Grant date: Mar 22, 1994
• Expiry date: Apr 6, 2012

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2239/53
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of determining the level of immunosuppression in a mammal involves determining the level of expression of at least one selected TCR subunit protein, or protein in the T lymphocyte signal transduction pathway, and comparing the level to that found in healthy individuals. The method is useful to identify patients having T lymphocytes capable of activation for autologous adoptive immunotherapy and for identifying agents which cause or reverse immunosuppression.